Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Silymarin × Clear all
NCT00487721 2014-03-31

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

University of Colorado, Denver

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡